LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc
Search

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

93.67 -1.13

Силна покупка

Обновена цена 8.05.2026 г., 17:11 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

93.32

Максимум

96.23

Ключови измерители

By Trading Economics

Приходи

5.4M

-48M

Продажби

6M

57M

Марж на печалбата

-82.974

Служители

414

EBITDA

5.1M

-43M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+41.41% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-565M

5.9B

Предишно отваряне

94.8

Предишно затваряне

93.67

Настроения в новините

By Acuity

48%

52%

160 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 23:58 ч. UTC

Печалби

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

DJ

Прочетени

7.05.2026 г., 22:57 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

DJ

Прочетени

7.05.2026 г., 23:52 ч. UTC

Печалби

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

DJ

Прочетени

7.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

DJ

Прочетени

7.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

DJ

Прочетени

7.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

DJ

Прочетени

7.05.2026 г., 23:11 ч. UTC

Печалби

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

DJ

Прочетени

7.05.2026 г., 23:06 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

DJ

Прочетени

7.05.2026 г., 23:05 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

DJ

Прочетени

7.05.2026 г., 23:04 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

DJ

Прочетени

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

DJ

Прочетени

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

DJ

Прочетени

7.05.2026 г., 23:02 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

DJ

Прочетени

7.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

DJ

Прочетени

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

DJ

Прочетени

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

DJ

Прочетени

7.05.2026 г., 22:42 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

DJ

Прочетени

7.05.2026 г., 22:33 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

DJ

Прочетени

7.05.2026 г., 22:32 ч. UTC

Печалби

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie: 68% of FY Income From International >MQG.AU

DJ

Прочетени

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:29 ч. UTC

Печалби

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:26 ч. UTC

Печалби

Macquarie to End Share Buyback Extended in November>MQG.AU

DJ

Прочетени

7.05.2026 г., 22:25 ч. UTC

Печалби

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

41.41% нагоре

12-месечна прогноза

Среден 136.62 USD  41.41%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

14

Купи

0

Задържане

0

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Средносрочен план

Bullish Evidence

All events are bullish.

Дългосрочен план

Bullish Evidence

Recent bullish events outweigh bearish events.

Настроение

By Acuity

160 / 347 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Други акции от сектора

LLY

Eli Lilly and Co.

952.3

↓-2.13%

JNJ

Johnson and Johnson

221.44

↓-0.1%

ABBV

AbbVie Inc

201.01

↓-0.81%

UNH

UnitedHealth Group Inc

372.74

↑ +1.5%

AZN

AstraZeneca PLC

182.67

↑ +0.91%
help-icon Live chat